{
  "generated_at": "2026-02-06T05:35:16Z",
  "company_id": "immatics",
  "company_name": "Immatics",
  "asset_count": 5,
  "change_count": 16,
  "assets": [
    {
      "asset_id": 20,
      "asset_name": "IMA401",
      "aliases": [
        "IMA401"
      ],
      "indications": [
        {
          "indication": "HNSCC, sqNSCLC, other solid cancers",
          "stage": "Phase 1",
          "therapeutic_area": "Oncology",
          "as_of_date": null
        }
      ]
    },
    {
      "asset_id": 18,
      "asset_name": "IMA402",
      "aliases": [
        "IMA402"
      ],
      "indications": [
        {
          "indication": "Melanoma, gynecologic cancers, other solid cancers",
          "stage": "Phase 1",
          "therapeutic_area": "Oncology",
          "as_of_date": null
        }
      ]
    },
    {
      "asset_id": 19,
      "asset_name": "IMA402 + ICI",
      "aliases": [
        "ICI",
        "IMA402",
        "IMA402 + ICI"
      ],
      "indications": [
        {
          "indication": "Melanoma, gynecologic cancers, other solid cancers (combo)",
          "stage": "Phase 1",
          "therapeutic_area": "Oncology",
          "as_of_date": null
        }
      ]
    },
    {
      "asset_id": 21,
      "asset_name": "Undisclosed bispecific",
      "aliases": [
        "Undisclosed bispecific"
      ],
      "indications": [
        {
          "indication": "Undisclosed",
          "stage": "Preclinical",
          "therapeutic_area": "Oncology",
          "as_of_date": null
        }
      ]
    },
    {
      "asset_id": 22,
      "asset_name": "Undisclosed cell therapy",
      "aliases": [
        "Undisclosed cell therapy"
      ],
      "indications": [
        {
          "indication": "Undisclosed",
          "stage": "Preclinical",
          "therapeutic_area": "Oncology",
          "as_of_date": null
        }
      ]
    }
  ]
}